*Tuesday, August 17th Webinar CANCELLED*
We regret to inform you that the webinar session on Wednesday, August 17th, 2016 from 10:00 a.m. to 12:00 p.m. (noon) is cancelled due to unforeseen technical issues. We wanted to give as much notice as possible so individuals can register for the alternate date (Tuesday, ... Read More
Hannah Lamb-Palmer
12
Aug2016
10
Aug2016
On June 24, 2016, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. Are you interested in learning more about the potential repercussions of these changes on Canadian drug prices and implications for pharmaceutical companies?
PDCI Market Access Inc., Canada’s leading pricing and reimbursement ... Read More
05
Aug2016
Results of the Notice and Comment Period on Incremental Reforms to the Compendium of Policies, Guidelines and Procedures
On December 4, 2015, the PMPRB announced the start of a Notice and Comment initiative to seek stakeholder feedback on two proposed amendments to the Compendium of Policies, Guidelines and Procedures: the “Reasonable ... Read More
21
Jul2016
Correction to the below TargetPharma (“PMPRB 2015 Annual Report”) sent out on July 21, 2016.
The PMPRB report tabled in Parliament was their report with respect to the Access to Information Act and to the Privacy Act and not the anticipated “2015 PMPRB Annual Report” which was not tabled and now ... Read More
03
May2016
The Patented Medicine Prices Review Board (PMPRB) has released its April 2016 NEWSletter. Some recent changes include:
Public Consultation on PMPRB Framework Modernization
In December 2015, the PMPRB released its 2015-2018 Strategic Plan, the culmination of a year-long strategic planning process that identified a new vision, a revised mission statement, and four ... Read More
03
May2016
In June/July 2015, PDCI Market Access and H3 Consulting conducted an on-line survey to gauge the interest, experience and expectation surrounding private payer product listing agreements (PLAs). There was tremendous response to that survey with 27 individuals (19 from industry and 8 from the private insurer community) participating in the ... Read More
22
Apr2016
To meet the needs of Quebec’s Ministry of Health and Social Services (MSSS), the Institut national d’excellence en santé et en services sociaux (INESSS) has developed a new drug review process for stable blood products for their addition to the Liste des produits du système du sang du Québec.
In addition, ... Read More
19
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here.
The pCPA has also updated the status of negotiations on brand name drugs, included in ... Read More
11
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics (SEBs) to guide negotiations and inform expectations. This information has not yet been posted on the pCPA website but is being shared with their permission.
Please see below for a copy ... Read More
30
Mar2016
Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective date of the following two CDR procedural revisions:
The timing of CDR review team’s responses being provided to the manufacturer, and
The revised CDR voluntary withdrawal procedure
The revised date for these two ... Read More